A subgroup analysis of the data has revealed promising efficacy in terms of OS among patients with Barcelona Clinic Liver Cancer (BCLC) C, Eastern Cooperative Oncology Group (ECOG) 1, presence of EHS, AFP levels<400 ng/ml, and viral hepatitis positivity, particularly HBV, when treated with immunotherapy combined with anti-angiogenetic agents. This evidence concerns the gene AFP and liver cancer.